SecBot SecBot
424B5 ·Filed May 19, 2026

ANVS

Annovis Bio, Inc.
BEARISH
Impact 7/10
Horizonimmediate Processed6mo ago SEC0001104659-26-063959
Notable filing: 424B5
Actionable Insight ▼ Bearish

Expect further downward pressure on ANVS as the market prices in substantial dilution. Monitor for final pricing and size, larger offerings amplify the negative impact. The company's cash runway extension is the only offsetting factor, but near-term stock performance will likely be weak.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$2.04
T+0 close · May 19, 2026 · via day close
Latest settled
−9.31%
T+60 · $1.85
Vs SPY
−14.32%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 20 $2.04entry
  2. T+1 · 6mo ago +5.39%α +5.20% · $2.15
  3. T+5 · 6mo ago −1.47%α −2.71% · $2.01
  4. T+20 · 5mo ago −14.22%α −14.96% · $1.75
  5. T+60 · 3mo ago −9.31%α −14.32% · $1.85
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Annovis Bio filed a preliminary 424B5 for an underwritten offering of common stock and warrants, with no final pricing disclosed. The company has a going concern, cash of $14.2M (insufficient for 12 months), and an accumulated deficit of $181.3M. The offering will be highly dilutive to existing shareholders.

Key Facts

  • Preliminary prospectus for offering of common stock and warrants (nine-tenths warrant per share, six-year term).
  • Cash and cash equivalents of $14.2M as of March 31, 2026, insufficient to fund operations for the next 12 months.
  • Accumulated deficit of $181.3M; going concern uncertainty noted.
  • Phase 3 Alzheimer's trial enrollment 85% complete; cash expected to last only until Q4 2026.
  • Prior registered direct offering in April 2026 raised $9.3M net at $1.90/unit.
  • This filing follows Q1 2026 earnings (May 15, 2026) that showed increased net loss and cash burn.

Financial Impact

Unknown offering size; no pricing disclosed. However, dilution will be significant given the company's $71M market cap and urgent need for capital.

dilutionshare countcash position

Risk Factors

  • Dilution from the offering may significantly reduce per-share value.
  • If the offering is larger than expected, selling pressure could be severe.
  • Failure to complete the offering would force a drastic reduction in operations or a distressed financing.
  • Phase 3 Alzheimer's trial results remain binary and could wipe out remaining value if negative.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001104659-26-063959
Document: 0001104659-26-063959-index-headers.html0001104659-26-063959
Document: 0001104659-26-063959-index.html0001104659-26-063959
Document: 0001104659-26-063959.txt0001104659-26-063959

US Market Status

Market Closed · Opens in 5h 49m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 19, 2026